Ann Pharmacol Pharm | Volume 2, Issue 9 | Review Article | Open Access
Nida Akhtar and Kamla Pathak*
Department of Pharmaceutics, Uttar Pradesh University of Medical Sciences, India
*Correspondance to: Kamla Pathak
Fulltext PDFParkinson’s disease (PD) is defined as the second most prevalent neurodegenerative disorder that has been characterized with a loss of dopaminergic neurons severely in cytoplasmic inclusions and substantia nigra. To treat both early and advanced stages of PD several therapeutic agents are available. However, the transport of therapeutic actives in to the brain has been a consistent challenge for researchers, because of the presence of blood-brain barrier (BBB). Various novel delivery carriers have been designed to deliver the drugs across BBB and the systems have been designed with an object to effectively target the drugs and overcoming the BBB. In some last decades, transdermal delivery carriers have gained extensive deliberations across the globe. These transdermal systems are depicted to be the most recent modalities in treating PD as they offer constant drug delivery, immediate effect as intestinal absorption in unneeded, and ease of application being a non-invasive technique. The present review explores the potential of transdermal delivery systems in order to deliver numerous therapeutic actives researched for PD therapy via transdermal route. Various trans-carriers such as patches, oil-based nanocarriers, nanoemulsions have been observed for the treatment of PD. The write up traces the reports on transdermal delivery carriers in PD and clinical study data to define the feasibility transdermal carriers.
Transcarriers; Transdermal delivery; Parkinson’s disease; Drug delivery systems; Clinical status
Akhtar N, Pathak K. Feasibility Assessment of Transdermal Drug Delivery Systems for Treatment of Parkinson's Disease. Ann Pharmacol Pharm. 2017; 2(9): 1090.